{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03183622",
      "OrgStudyIdInfo": {
        "OrgStudyId": "ALLO-ASC-BI-102"
      },
      "Organization": {
        "OrgFullName": "Anterogen Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial",
      "OfficialTitle": "A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1 Clinical Trial of ALLO-ASC-BI-101"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2018",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 2015",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 2017",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2017",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "June 8, 2017",
      "StudyFirstSubmitQCDate": "June 8, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 12, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 8, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 10, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Anterogen Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial(ALLO-ASC-BI-101) for 23 months.",
      "DetailedDescription": "This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial (ALLO-ASC-BI-101) for 23 months.\n\nALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Burn"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Deep Second-Degree Burn Wound"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Observational",
      "PatientRegistry": "No",
      "DesignInfo": {
        "DesignObservationalModelList": {
          "DesignObservationalModel": [
            "Case-Only"
          ]
        },
        "DesignTimePerspectiveList": {
          "DesignTimePerspective": [
            "Prospective"
          ]
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "5",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "ALLO-ASC-DFU treatment",
            "ArmGroupDescription": "Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-BI-101",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: ALLO-ASC-DFU"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "ALLO-ASC-DFU",
            "InterventionDescription": "ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.\n\nThis tudy is a follow-up study without intervention.\n\nOther Names:\n\nAllogenic adipose-derived mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "ALLO-ASC-DFU treatment"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability",
            "PrimaryOutcomeDescription": "Evaluation of AE",
            "PrimaryOutcomeTimeFrame": "up to 24 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Vancouver Burn Scar Scale",
            "SecondaryOutcomeDescription": "Evaluation of Vancouver Burn Scar Scale",
            "SecondaryOutcomeTimeFrame": "Every time of visit for follow up to 24 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSubjects who are treated with ALLO-ASC-DFU sheet in phase 1 clinical trial of ALLO-ASC-BI-101.\nA subject who is willing to follow the protocol and provide informed consent on screening, given that the information with respect to the clinical trial is provided.\n\nExclusion Criteria:\n\n1. Subjects who are considered not suitable for the study by the principal investigator. (For example, Subjects requiring surgical procedure on target site)",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      },
      "StudyPopulation": "Subject is enrolled who are treated with ALLO-ASC-DFU sheet in phase 1 clinical trial of ALLO-ASC-BI-101",
      "SamplingMethod": "Probability Sample"
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Wook Chun, PhD",
            "OverallOfficialAffiliation": "Hallym University Medical Center",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hallym university Medical Center",
            "LocationCity": "Seoul",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M16837",
            "ConditionBrowseLeafName": "Wounds and Injuries",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4478",
            "ConditionBrowseLeafName": "Burns",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC26",
            "ConditionBrowseBranchName": "Wounds and Injuries"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M11052",
            "InterventionBrowseLeafName": "Mitogens",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M17833",
            "InterventionBrowseLeafName": "Endothelial Growth Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3369",
            "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infl",
            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
          }
        ]
      }
    }
  }
}